Case Report: The Added Value of Liquid Biopsy in Advanced Colorectal Cancer From Clinical Case Experiences

Liquid biopsy represents a valid strategy for tumor molecular characterization. It gives the opportunity to bypass tumor heterogeneity, to monitor tumor characteristics during the course of treatment, and to perform the analysis even when tumor tissue is not available or inadequate. In the clinical...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Paola Ulivi, Alessandro Passardi, Giorgia Marisi, Elisa Chiadini, Chiara Molinari, Matteo Canale, Luigi Pasini, Fabio Ferroni, Giovanni Luca Frassineti, Giulia Bartolini, Manlio Monti
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	CtDNA metastatic colorectal cancer RAS mutations case report Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/83b520a2d9594b96bbf750402e9697ce
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:83b520a2d9594b96bbf750402e9697ce
record_format	dspace
spelling	oai:doaj.org-article:83b520a2d9594b96bbf750402e9697ce2021-11-10T07:28:57ZCase Report: The Added Value of Liquid Biopsy in Advanced Colorectal Cancer From Clinical Case Experiences1663-981210.3389/fphar.2021.745701https://doaj.org/article/83b520a2d9594b96bbf750402e9697ce2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fphar.2021.745701/fullhttps://doaj.org/toc/1663-9812Liquid biopsy represents a valid strategy for tumor molecular characterization. It gives the opportunity to bypass tumor heterogeneity, to monitor tumor characteristics during the course of treatment, and to perform the analysis even when tumor tissue is not available or inadequate. In the clinical practice of metastatic colorectal cancer, tumor molecular characterization is crucial for patient management, as RAS and BRAF status could influence the treatment choice. Although for this type of cancer tumor tissue is usually available at diagnosis, liquid biopsy could give complementary information and could permit monitoring of the mutation status during the course of treatment. At present, there are no clinical indications for its use in clinical practice. However, we report four clinical cases for which liquid biopsy analysis gave integrative information with respect to tumor tissue characterization, which permits us to understand the unresponsiveness of patients to treatment, with potential implications in patient’s management.Paola UliviAlessandro PassardiGiorgia MarisiElisa ChiadiniChiara MolinariMatteo CanaleLuigi PasiniFabio FerroniGiovanni Luca FrassinetiGiulia BartoliniManlio MontiFrontiers Media S.A.articleCtDNAmetastatic colorectal cancerRASmutationscase reportTherapeutics. PharmacologyRM1-950ENFrontiers in Pharmacology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	CtDNA metastatic colorectal cancer RAS mutations case report Therapeutics. Pharmacology RM1-950
spellingShingle	CtDNA metastatic colorectal cancer RAS mutations case report Therapeutics. Pharmacology RM1-950 Paola Ulivi Alessandro Passardi Giorgia Marisi Elisa Chiadini Chiara Molinari Matteo Canale Luigi Pasini Fabio Ferroni Giovanni Luca Frassineti Giulia Bartolini Manlio Monti Case Report: The Added Value of Liquid Biopsy in Advanced Colorectal Cancer From Clinical Case Experiences
description	Liquid biopsy represents a valid strategy for tumor molecular characterization. It gives the opportunity to bypass tumor heterogeneity, to monitor tumor characteristics during the course of treatment, and to perform the analysis even when tumor tissue is not available or inadequate. In the clinical practice of metastatic colorectal cancer, tumor molecular characterization is crucial for patient management, as RAS and BRAF status could influence the treatment choice. Although for this type of cancer tumor tissue is usually available at diagnosis, liquid biopsy could give complementary information and could permit monitoring of the mutation status during the course of treatment. At present, there are no clinical indications for its use in clinical practice. However, we report four clinical cases for which liquid biopsy analysis gave integrative information with respect to tumor tissue characterization, which permits us to understand the unresponsiveness of patients to treatment, with potential implications in patient’s management.
format	article
author	Paola Ulivi Alessandro Passardi Giorgia Marisi Elisa Chiadini Chiara Molinari Matteo Canale Luigi Pasini Fabio Ferroni Giovanni Luca Frassineti Giulia Bartolini Manlio Monti
author_facet	Paola Ulivi Alessandro Passardi Giorgia Marisi Elisa Chiadini Chiara Molinari Matteo Canale Luigi Pasini Fabio Ferroni Giovanni Luca Frassineti Giulia Bartolini Manlio Monti
author_sort	Paola Ulivi
title	Case Report: The Added Value of Liquid Biopsy in Advanced Colorectal Cancer From Clinical Case Experiences
title_short	Case Report: The Added Value of Liquid Biopsy in Advanced Colorectal Cancer From Clinical Case Experiences
title_full	Case Report: The Added Value of Liquid Biopsy in Advanced Colorectal Cancer From Clinical Case Experiences
title_fullStr	Case Report: The Added Value of Liquid Biopsy in Advanced Colorectal Cancer From Clinical Case Experiences
title_full_unstemmed	Case Report: The Added Value of Liquid Biopsy in Advanced Colorectal Cancer From Clinical Case Experiences
title_sort	case report: the added value of liquid biopsy in advanced colorectal cancer from clinical case experiences
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/83b520a2d9594b96bbf750402e9697ce
work_keys_str_mv	AT paolaulivi casereporttheaddedvalueofliquidbiopsyinadvancedcolorectalcancerfromclinicalcaseexperiences AT alessandropassardi casereporttheaddedvalueofliquidbiopsyinadvancedcolorectalcancerfromclinicalcaseexperiences AT giorgiamarisi casereporttheaddedvalueofliquidbiopsyinadvancedcolorectalcancerfromclinicalcaseexperiences AT elisachiadini casereporttheaddedvalueofliquidbiopsyinadvancedcolorectalcancerfromclinicalcaseexperiences AT chiaramolinari casereporttheaddedvalueofliquidbiopsyinadvancedcolorectalcancerfromclinicalcaseexperiences AT matteocanale casereporttheaddedvalueofliquidbiopsyinadvancedcolorectalcancerfromclinicalcaseexperiences AT luigipasini casereporttheaddedvalueofliquidbiopsyinadvancedcolorectalcancerfromclinicalcaseexperiences AT fabioferroni casereporttheaddedvalueofliquidbiopsyinadvancedcolorectalcancerfromclinicalcaseexperiences AT giovannilucafrassineti casereporttheaddedvalueofliquidbiopsyinadvancedcolorectalcancerfromclinicalcaseexperiences AT giuliabartolini casereporttheaddedvalueofliquidbiopsyinadvancedcolorectalcancerfromclinicalcaseexperiences AT manliomonti casereporttheaddedvalueofliquidbiopsyinadvancedcolorectalcancerfromclinicalcaseexperiences
_version_	1718440484085432320

Case Report: The Added Value of Liquid Biopsy in Advanced Colorectal Cancer From Clinical Case Experiences

Ejemplares similares